Insulin-specific autoreactive T cell

Insulin-specific autoreactive T cells are T lymphocytes (both CD4(+) and CD8(+)) that recognize and respond to peptide epitopes derived from the insulin molecule presented via MHC class II and class I molecules, respectively[1][2][4][5][6][7]. These cells are critical mediators of pancreatic islet β-cell destruction in type 1 diabetes, and their reactivity often focuses on specific insulin epitopes such as B:9–23 (for CD4(+)) or PPI 6–14 (for CD8(+)), among others. The presence and activity of these T cells serve as a major driver of the autoimmune response in T1D, strongly influenced by genetic factors (especially HLA haplotypes) and environmental triggers (e.g., viral infections, molecular mimicry). Current therapeutic research is focused on understanding their behavior to develop targeted immunotherapies that aim to induce tolerance specifically to insulin-derived antigens, with the goal of halting or reversing β-cell loss in diabetes. Monitoring insulin-specific autoreactive T cells is also an active area of biomarker development for disease prediction and immune monitoring in both clinical and research settings[5][6][7].

Other names

Insulin-reactive T cellInsulin-specific T lymphocyteInsulin-specific CD4 T cellInsulin-specific CD8 T cellIslet-reactive T cell

For general immunosuppressants: Broad T cell inhibition For tolerogenic vaccines: Induction of antigen-specific tolerance (immune deviation or deletion)